IN2012DN02521A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02521A
IN2012DN02521A IN2521DEN2012A IN2012DN02521A IN 2012DN02521 A IN2012DN02521 A IN 2012DN02521A IN 2521DEN2012 A IN2521DEN2012 A IN 2521DEN2012A IN 2012DN02521 A IN2012DN02521 A IN 2012DN02521A
Authority
IN
India
Prior art keywords
administering
preventing
invention features
antagonist antibody
interstitial cystitis
Prior art date
Application number
Other languages
English (en)
Inventor
Ariel Ates Pios
Kristian Todd Poulsen
David Louis Shelton
Joerg Zeller
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of IN2012DN02521A publication Critical patent/IN2012DN02521A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2521DEN2012 2009-08-28 2010-08-23 IN2012DN02521A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23790109P 2009-08-28 2009-08-28
PCT/IB2010/053787 WO2011024113A1 (fr) 2009-08-28 2010-08-23 Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine

Publications (1)

Publication Number Publication Date
IN2012DN02521A true IN2012DN02521A (fr) 2015-08-28

Family

ID=42983393

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2521DEN2012 IN2012DN02521A (fr) 2009-08-28 2010-08-23

Country Status (14)

Country Link
US (6) US8623366B2 (fr)
EP (2) EP2470207A1 (fr)
JP (5) JP2011046710A (fr)
KR (1) KR101519192B1 (fr)
CN (2) CN102740884A (fr)
AU (1) AU2010288194B2 (fr)
BR (1) BR112012004464B8 (fr)
CA (1) CA2771186C (fr)
ES (1) ES2912569T3 (fr)
IL (1) IL218228B (fr)
IN (1) IN2012DN02521A (fr)
MX (1) MX2012002464A (fr)
RU (1) RU2535074C2 (fr)
WO (1) WO2011024113A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20080200A (en) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (fr) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine
EP2709662B1 (fr) 2011-05-20 2019-07-31 AlderBio Holdings LLC Utilisation d'anticorps ou de fragments d'anticorps anti-cgrp ou anti-cgrp-r dans le traitement ou la prévention de formes chroniques et aiguës de la diarrhée
BR112013029959A8 (pt) 2011-05-20 2021-09-08 Alderbio Holdings Llc Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante
EP3662932B1 (fr) 2011-05-20 2021-04-07 H. Lundbeck A/S Compositions anti-cgrp et leur utilisation
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
LT3119431T (lt) * 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
SG10202109689QA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Humanized anti-pacap antibodies and uses thereof
WO2018055574A1 (fr) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Traitement de la migraine réfractaire
EP3774881A1 (fr) 2018-04-02 2021-02-17 Amgen Inc. Compositions d'érénumab et utilisations de celles-ci
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
SG11202104352XA (en) * 2018-12-18 2021-05-28 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
TWI839435B (zh) 2019-01-08 2024-04-21 丹麥商Ｈ．朗德貝克公司 使用抗cgrp 抗體急性治療和快速治療頭痛

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE71195B1 (en) 1989-07-10 1997-02-12 Amylin Corp Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related disorders
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (fr) 1990-08-29 2007-04-03 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994021665A1 (fr) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Recepteurs clones et methodes de criblage associees
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
CA2761116A1 (fr) 1995-04-27 1996-10-31 Amgen Fremont Inc. Anticorps humains derives d'une xenosouris immunisee
WO1997009046A1 (fr) 1995-09-05 1997-03-13 Smithkline Beecham Corporation Composes et procedes associes
AU2731797A (en) 1996-04-15 1997-11-19 University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP3734315B2 (ja) 1996-08-26 2006-01-11 株式会社小松製作所 曲げ加工方法および曲げ加工装置
CA2264942A1 (fr) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Composes et methodes
EA004037B1 (ru) 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
WO1998056779A1 (fr) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyle benzamides utiles comme antagonistes du recepteur de peptides lies au gene de la calcitonine
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
US6552043B1 (en) 1998-09-30 2003-04-22 Merck Sharpe & Dohme Ltd. Benzimidazolinyl piperidines as CGRP ligands
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (fr) * 1999-02-23 2000-08-30 Warner-Lambert Company Utilisation d'un analogue de la gabapentine pour la fabrication d'un médicament pour la prevention et le traitement des douleurs viscérales
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
JP4603261B2 (ja) 2001-09-27 2010-12-22 メルク・シャープ・エンド・ドーム・コーポレイション ヒト化カルシトニン遺伝子関連ペプチド受容体をコードする単離ｄｎａ分子、関連する非ヒトトランスジェニック動物及びアッセイ方法
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
WO2003085089A2 (fr) 2002-03-29 2003-10-16 Schering Corporation Anticorps monoclonaux humains anti-interleukine-5 et procedes et compositions les contenant
WO2003093472A2 (fr) 2002-05-06 2003-11-13 Grünenthal GmbH Acides nucleiques liant le cgrp
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
PL374017A1 (en) 2002-06-05 2005-09-19 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
RS52750B (sr) 2002-08-12 2013-08-30 Birkir Sveinsson Upotreba cgrp antagonista za lečenje psorijaze
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AU2003298816C1 (en) 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2004087649A2 (fr) 2003-03-14 2004-10-14 Merck & Co., Inc. Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
AU2004222328B2 (en) 2003-03-14 2009-10-08 Merck Sharp & Dohme Corp. Aryl spirohydantoin CGRP receptor antagonists
AU2004221891B2 (en) 2003-03-14 2009-11-19 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin CGRP receptor antagonists
DE602004013563D1 (de) 2003-03-14 2008-06-19 Merck & Co Inc Rantagonisten
AU2004222378B2 (en) 2003-03-14 2008-08-14 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2522024A1 (fr) 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs de cgrp
WO2004097421A2 (fr) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
WO2005041757A2 (fr) 2003-10-29 2005-05-12 University Of Rochester Detection de neuropeptides associes a des douleurs pelviennes et leurs utilisations
DE102004008261B3 (de) 2004-02-20 2005-09-29 Mtu Friedrichshafen Gmbh Verfahren zur Steuerung und Regelung einer Brennkraftmaschinen-Generator-Einheit
WO2005084672A1 (fr) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Antagonistes de cgrp selectionnes, procedes de fabrication et utilisation en tant que medicament
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
JP2007533685A (ja) 2004-04-20 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたｃｇｒｐアンタゴニストの使用
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) * 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (fr) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments
WO2007025212A2 (fr) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Utilisation de bloqueurs des canaux sodiques pour traiter les douleurs viscerales, ou les douleurs provoquees par un traitement anticancereux
DE602006012513D1 (de) 2005-08-26 2010-04-08 Healthpartners Res Foundation Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
JP2009508970A (ja) 2005-09-21 2009-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 疼痛の局所造影および治療のためのシステム、組成物並びに方法
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
RS20080200A (en) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
DE602006019304D1 (de) 2005-11-18 2011-02-10 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
WO2007076336A1 (fr) 2005-12-22 2007-07-05 Eli Lilly And Company Traitement de la migraine avec des anticorps anti-cgrp
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
ATE469895T1 (de) 2006-07-21 2010-06-15 Vertex Pharma Cgrp-rezeptorantagonisten
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090104234A1 (en) 2007-10-23 2009-04-23 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
PL2265288T3 (pl) 2008-03-04 2017-01-31 Labrys Biologics Inc Sposoby leczenia bólu zapalnego
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
WO2010006168A2 (fr) 2008-07-09 2010-01-14 University Of Rochester Procédés de traitement du cancer à l'aide d'un agent modulant l'activité du récepteur du peptide lié au gène de la calcitonine (« cgrp »)
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (fr) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists

Also Published As

Publication number Publication date
US20140314767A1 (en) 2014-10-23
WO2011024113A1 (fr) 2011-03-03
US20210047397A1 (en) 2021-02-18
KR20120047978A (ko) 2012-05-14
JP2011046710A (ja) 2011-03-10
BR112012004464B8 (pt) 2021-05-25
JP2019163291A (ja) 2019-09-26
AU2010288194A1 (en) 2012-03-01
EP3165236A1 (fr) 2017-05-10
IL218228B (en) 2019-01-31
KR101519192B1 (ko) 2015-05-11
CA2771186C (fr) 2018-01-02
US20140308290A1 (en) 2014-10-16
US20120225075A1 (en) 2012-09-06
BR112012004464A2 (pt) 2016-11-16
US20170073412A1 (en) 2017-03-16
US8623366B2 (en) 2014-01-07
RU2012106468A (ru) 2013-10-10
CN107441487A (zh) 2017-12-08
JP2021152058A (ja) 2021-09-30
CA2771186A1 (fr) 2011-03-03
MX2012002464A (es) 2012-03-14
JP2015193670A (ja) 2015-11-05
ES2912569T3 (es) 2022-05-26
AU2010288194B2 (en) 2013-08-29
IL218228A0 (en) 2012-04-30
RU2535074C2 (ru) 2014-12-10
US20190085072A1 (en) 2019-03-21
BR112012004464B1 (pt) 2021-01-12
JP2018024661A (ja) 2018-02-15
CN107441487B (zh) 2021-09-14
EP2470207A1 (fr) 2012-07-04
EP3165236B1 (fr) 2022-03-16
US10597448B2 (en) 2020-03-24
CN102740884A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
IN2012DN02521A (fr)
IL261348A (en) An isolated antibody or part thereof that binds to CD100 for use in the treatment of autoimmune disease, inflammatory disease and/or cancer
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2013123432A3 (fr) Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
MY164647A (en) Cea antibodies
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
IT1399435B1 (it) Anta per mobili con pannello amovibile - intercambiabile.
MY181969A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
WO2013033627A3 (fr) Diagnostic et traitement de l'arthrite à l'aide de l'épigénétique
MX2013004979A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
EA032986B1 (ru) Пирролобензодиазепины
MX2013002270A (es) Inmonoglubinas de dominio variable doble y usos de las mismas.
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
EP2539470A4 (fr) Procédés pour le diagnostic, le pronostic et le traitement de maladies auto-immunes
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX362492B (es) Macrociclos peptidomiméticos.
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
CR20120371A (es) Antagonistas de pcsk9
EP2569330A4 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
BRPI0909179A2 (pt) Composição farmacêutica, e, método de tratamento de uma doença autoimune.
IN2014DN05885A (fr)
WO2012149478A3 (fr) Agents utiles pour le traitement de l'ataxie de friedreich et autres maladies neurodégénératives
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"